OEM Customized Antiparacitic Pharmaceuticals - Ceftriaxone for inj. – KeMing Medicines Detail:
FOB Price | Inquiry |
Min.Order Quantity | 50,000 Vials |
Supply Ability | 9,000,000 bottles/Month |
Port | Shanghai |
Payment Terms | T/T in advance |
Product Detail | |
Product name | Ceftriaxone for inj. |
Specification | 1g+10ml |
Description | A white, crystalline powder |
Standard | BP |
Package | 1Vials+1 ampoule/box |
Transportation | Ocean,Land,Air |
Certificate | GMP |
Price | Inquiry |
Quality guaranteeperiod | for 36 months |
Product Description | [Primary indication] Third generation cephalosporin Used for treating neonatal meningitis and sepsis caused by susceptible gram negative organisms(E Coli,Klebsiella,H flu). It competes with bilirubin for binding sites on albumin. |
Product detail pictures:
Related Product Guide:
Disease, Doctors, Drugs and Vitamins!
Cholesterol Drugs and Low Vitamin D Along With Other Hormone Levels
Assume full accountability to satisfy all demands of our consumers; reach ongoing advancements by endorsing the expansion of our purchasers; come to be the final permanent cooperative partner of clients and maximize the interests of clientele for OEM Customized Antiparacitic Pharmaceuticals - Ceftriaxone for inj. – KeMing Medicines, The product will supply to all over the world, such as: Philadelphia, Bolivia, Paraguay, We've been always creating new technology to streamline the production, and give products with competitive prices and high quality! Customer satisfaction is our priority! You can let us know your idea to develop unique design for your own model to prevent too much similar parts in the market! We are going to present our best service to satisfy all your needs! Remember to contact us right away!
By Ivy from Grenada - 2018.06.19 10:42
The customer service staff is very patient and has a positive and progressive attitude to our interest, so that we can have a comprehensive understanding of the product and finally we reached an agreement, thanks!
By Miranda from Philippines - 2017.11.29 11:09